Simplifying Global Compliance
FDA Approves Genentech’s Lucentis for Additional Indication in DME
Washington Drug Letter
The FDA has approved Genentech’s Lucentis for an additional indication in diabetic macular edema (DME), making it the first and only agency-approved treatment for the condition.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing